Finally, by investigating the relative impact of the risk factors associated with TTFT, SF3B1 mutations was the most significant marker followed by XPO1 mutations in Binet stage A M-CLL patients, while for Binet stage A U-CLL cases, SF3B1 mutations was the most significant factor by far (Supplementary Fig. S7). This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.